No Data
Kangmei Pharmaceutical Co., Ltd. (SHSE:600518) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Kangmei Pharmaceutical (SHSE:600518 Investor Three-year Losses Grow to 49% as the Stock Sheds CN¥1.2b This Past Week
Kangmei Pharmaceutical (600518.SH): Not currently involved in AI medicine.
Kangmei Pharmaceutical (600518.SH) stated on the interactive platform on November 22 that the business of the company does not currently involve AI medicine.
Kangmei Pharmaceutical (600518.SH): Currently, there are no plans for restructuring.
On November 22, Gelonghui reported that Kangmei Pharmaceutical (600518.SH) stated on the interactive platform that the company currently has no plans for reorganization and will strictly follow relevant regulations to timely fulfill its information disclosure obligations. Relevant information should be based on the company's announced disclosures. The company will continue to promote and implement the "12355" global strategy, positioning itself as a smart traditional chinese medicine health brand enterprise centered on traditional chinese medicine pieces. It will focus on two main strategic lines: "creating a comprehensive chain of traditional chinese medicine pieces industry" and "providing specialized medical and health services for general well-being," with five main aspects: traditional chinese medicine, medical care and wellness, traditional chinese medicine city, health products, and pharmaceutical commerce.
Kangmei Pharmaceutical (600518.SH) has seen no major changes in its fundamentals, and its profitability still needs further recovery.
Gelonghui November 11th | Kangmei Pharmaceutical (600518.SH) announced that on November 11, 2024, the company's stocks continued to hit the limit up, with a significant short-term increase in stock prices. In the first three quarters of 2024, the company achieved revenue of 3873.5583 million yuan, with a net income attributable to shareholders of the listed company of 5.0155 million yuan, and a net income attributable to shareholders of the listed company after deducting non-recurring gains and losses of -179.5222 million yuan. The company's production operation is currently normal, and the fundamentals have not undergone significant changes, with profitability still needing further recovery. The board of directors of the company confirmed, in addition to what has been publicly disclosed.
Kangmei Pharmaceutical's (SHSE:600518) Solid Earnings Are Supported By Other Strong Factors
